ClinicalTrials.gg
CompletedNCT06986772Updated Sep 4, 2025

TGRX-678 Pharmacokinetic Mass Balance

A Phase 1 interventional study of [14C]TGRX-678 in Chronic Myeloid Leukemia, sponsored by Shenzhen TargetRx Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Shenzhen TargetRx Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China — 11 open to participants now, 14 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China.

Enrollment
36th of 37
6 · median 144
Started
2025
with 1 other
Phase 1
9 of 49
1 open now
Registered
44th of 49
by date

Among the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, this one is the 36th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 in phase 1, and was the 44th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

11 of the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, or all of them as a file.
02

Study summary

This is a pharmacokinetic study for [14C]TGRX-678 on mass balance to evaluate distribution, metabolism and excretion of TGRX-678, a tyrosine kinase inhibitor indicated for treatment of chronic myeloid leukemia.

Read the detailed description

This study is designed as a single-center, single-dose, non-randomized and open-label study. The study will be conducted in healthy male participants to evaluate distribution, metabolic pathways and route of excretion of TGRX-678 using the Carbon-14 labelled isotope of TGRX-678 compound. Safety and pharmacokinetic evaluation will also be conducted.

03

Conditions studied

  • Chronic Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult males
  • age between 18 and 45 (both included) years old
  • body weight index between 19.0 and 26.0 kg/m2 (both included, and body weight not lower than 50 kg
  • can volunteeringly consent
  • can communicate well with investigators and complete study according to protocol requirements

Exclusion criteria

Exclusion Criteria:

  • abnormal and of clinical significance results on physical exam, regular laboratory tests, thyroid function, anal check, chest x-ray, abdominal ultrasound check or 12-lead
  • positive test results on surface antigen/ E antigen, antibody, antigen/antibody or syphylus antibody
  • abnornal and of clinical significance results on eye exam
  • usage of any inducers or inhibitors for drug metabolism enzymes (especially ) within 30 days of screening
  • usage of any prescriptional drug, OTC drug, herbal medicine, traditional Chinese medicine, or food supplements (i.e., vitamins, calcium) within 14 days of screening
  • history of any serious diseases or any conditions that at investigator's discretion may affect study results
  • have condition that may affect drug absoption
  • received major surgery or with un-healed surgical wounds within 6 months of screening
  • have allergies to at least 2 substances or at investigator's discretion may be allergic to drug or any
  • have hemorrhoids; have history of or is having conditions that cause bloody feces, irritable bowel syndrome, or inflammatory bowel disease
  • habitutory constipation or diarrhea
  • alcohol abuse, or frequent use of alcohol within 6 months of screening
  • smoking of more than 5 cigarettes per day within 3 months of screening, or habitutory use of nicotine products and cannot quit during study
  • drug abuse, or use of soft drug (marajuana) within 3 months of screening, or use of hard drug (phenylamine or PCP type drugs) within 1 year of screening, or tested positive in urine drug test during screening
  • habitutory use of grape fruit juice, or overuse of tea, coffee or caffeinated drugs, and cannot quit during study
  • long-term occupational exposure to radioactive conditions, or have history of significant radioactive substance exposure or participated in clinical study using radioactive-labeled drugs within 1 year of current study
  • Having difficulties to receive venous needle puncture, or cannot tolerate venous needle puncture, or history of hematophobia or needle sickness
  • Participation in any other clinical studies within 3 months before screening
  • Reception of vaccine within 1 months before screening, or planning to be vaccinated during the study
  • Planning to have children or donate sperms during the study and within 1 year after the study, or Not agreeing to take measures during and within 1 year after study completion
  • Blood donation or blood loss of > 400 ml within 3 months before screening; blood donation or blood loss of > 200 ml within 1 month before screening; reception of blood transfusion within 1 months before screening; received blood donation within 1 months of study, or planning to donate blood within 3 months after study completion
  • Having special dietary requirements and unable to follow the uniform dietary plan in the study
  • Any conditions that the investigator deemed unfit for the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    TGRX-678

    healthy male subjects will be given 240mg/250uCi\[14C\]TGRX-678 in suspension

    Drug: [14C]TGRX-678

Interventions

  • Healthy subjects will be given TGRX-678 240 mg orally on day 1.

06

What researchers measure

Primary outcomes

  1. Urine radioactivity

    \[C14\]TGRX-678 radioactivity detected in urine

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

  2. Fecal radioactivity

    \[C14\]TGRX-678 radioactivity detected in feces

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

  3. Plasma AUC (Area under curve) percentage

    percentage of \[C14\]TGRX-678 radioactivity in plasma

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

  4. Urine %Dose

    percentage of \[C14\]TGRX-678 radioactivity in urine

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

  5. Fecal %Dose

    percentage of \[C14\]TGRX-678 radioactivity in feces

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

  6. Plasma Cmax

    Maximum concentration of \[C14\]TGRX-678 measured in plasma

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

  7. Plasma Tmax

    Time to maximum concentration of \[C14\]TGRX-678 measured in plasma

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

  8. Plasma AUC(0-t)

    Area under curve for TGRX-678 plasma concentration from before dose to last measureable timepoint

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing

Secondary outcomes

  1. Adverse events/serious adverse events

    to record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Day-1 (day before dosing), Day 1 to Day 54 after dosing or the day sample collection is completed

07

Study locations

1 site
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Aug 2025, 1 month.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 23, 2025
StartActual
Jul 7, 2025
Primary completionActual
Aug 17, 2025
CompletionActual
Aug 25, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06986772
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Responsible party
Sponsor
First posted
May 23, 2025
Start date
Jul 7, 2025
Primary completion
Aug 17, 2025
Completion
Aug 25, 2025
Last update
Sep 4, 2025

Study contacts

Liyan Miao, MD
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meribatinib

Start the discussion